Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCOAG: PCC in Trauma Hemorrhage
NCT03218722Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of balfaxar in hemorrhagic shock, acute traumatic coagulopathy (ATC), sponsored by CHU Grenoble Alpes. Started Dec 2017; status: completed.
02
Drugs
balfaxar
03
Conditions
hemorrhagic shockacute traumatic coagulopathy (ATC)
Beyond the preview
Go deeper on NCT03218722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218722.